Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services.
Questions
1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20)
2. What factors should physicians consider before prescribing inhaled therapies to patients with COPD? (0:52)
3. What has been the impact of the COVID-19 pandemic on the provision of pulmonary rehabilitation services for patients with COPD? (2:15)
4. What factors should be considered when restarting these programs, and how can we adapt these programs in case of future lockdowns? (3:55)
5. What advice would you give patients with COPD with regard to mask-wearing during the pandemic? (5:15)
Disclosures: Brian Carlin has taken part in speaker bureaus for GlaxoSmithKline, Sunovion, Mylan, Theravance, Monagha and Philips Respironics.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the CHEST 2020 Annual Meeting (Virtual).
